NPDT Evaluation in Children With CFTR and (PSC) (NPD)
Primary Purpose
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
nasal potential difference testing
Sponsored by
About this trial
This is an observational trial for Primary Sclerosing Cholangitis focused on measuring PSC, IBD, CFTR
Eligibility Criteria
Inclusion Criteria: 12 years of age and older Must have diagnosis of primary sclerosing cholangitis and/or inflammatory bowel disease Absence of other liver disease, such as viral hepatitis, drug-induced liver disease, and metabolic/hereditary liver disease No exclusion based on sex, race, and ethnic background
Sites / Locations
- Beth Israel Deaconess Medical Center
Outcomes
Primary Outcome Measures
CFTR DNA analysis
Secondary Outcome Measures
Nasal potential difference testing
Sweat test
Full Information
NCT ID
NCT00179439
First Posted
September 12, 2005
Last Updated
December 11, 2017
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Boston Children's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00179439
Brief Title
NPDT Evaluation in Children With CFTR and (PSC)
Acronym
NPD
Official Title
Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)
Study Type
Observational
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
January 2004 (Actual)
Primary Completion Date
January 2006 (Actual)
Study Completion Date
January 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Boston Children's Hospital
4. Oversight
5. Study Description
Brief Summary
The investigators hypothesize that PSC in children is associated with mutations and functional changes of the cystic fibrosis (CF) gene.
Detailed Description
The purpose of this protocol is to perform Nasal Transepithelial Potential Difference (NTPD) testing to assess the function of the cystic fibrosis gene product, a chloride channel referred to as CFTR, in patients diagnosed with PSC and/or inflammatory bowel disease in childhood and currently 12 years of age and greater.
Dr. Freedman's laboratory has shown that there is an increased prevalence of CFTR abnormalities in adults with PSC as demonstrated by genotype and phenotype analysis. We hypothesize that abnormalities in CFTR based on exhaustive genotype and phenotype assessments are associated with the presence of PSC in children. We would like to enroll patients with inflammatory bowel disease and no PSC to use as a "control group".
Subjects with PSC and/or inflammatory bowel disease diagnosed in childhood, currently aged 12 years and above, will be enrolled in study protocols at Children's Hospital in Boston, which will have received their local IRB approval. The only role for BIDMC will be to perform NTPD testing on these subjects. No other assessment or testing will be performed at our site. We will not be involved in any other aspect of care for these subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Keywords
PSC, IBD, CFTR
7. Study Design
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
nasal potential difference testing
Primary Outcome Measure Information:
Title
CFTR DNA analysis
Secondary Outcome Measure Information:
Title
Nasal potential difference testing
Title
Sweat test
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
12 years of age and older
Must have diagnosis of primary sclerosing cholangitis and/or inflammatory bowel disease
Absence of other liver disease, such as viral hepatitis, drug-induced liver disease, and metabolic/hereditary liver disease
No exclusion based on sex, race, and ethnic background
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harpreet Pall, MD
Organizational Affiliation
Boston Children's Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Steven D Freedman, MD, PhD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Learn more about this trial
NPDT Evaluation in Children With CFTR and (PSC)
We'll reach out to this number within 24 hrs